Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 9
Submit an article Journal homepage
32
Views
13
CrossRef citations to date
0
Altmetric
Review

Inhibitors of Aurora kinases for the treatment of cancer

Daniele Fancelli Nerviano Medical Sciences, BU-Oncology, Viale Pasteur, 10, 20014 Nerviano (MI), Italy
&
Jürgen Moll Nerviano Medical Sciences, BU-Oncology, Viale Pasteur, 10, 20014 Nerviano (MI), Italy
Pages 1169-1182 | Published online: 02 Dec 2005

Bibliography

  • GUMIREDDY K, REDDY MV,COSENZA SC et al.: 0N01910, a non-ATP-competitive small molecule inhibitor of Plkl, is a potent anticancer agent. Cancer Cell (2005) 7(3):275–286.
  • MAYER TU, KAPOOR TM, HAGGARTY SJ, KING RW, SCHREIBER SL, MITCHISON TJ: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 286(5441):971–974.
  • KEEN N, TAYLOR S: Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer (2004) 4(12):927–936.
  • •A systematic update on the best characterised Aurora inhibitors.
  • MARUMOTO T, ZHANG D, SAYA H: Aurora-A — a guardian of poles. Nat. Rev. Cancer (2005) 5(1):42–50.
  • •This paper represents a good entry point in Aurora-A biology.
  • MONTEMBAULT E, PRIGENT C: Aurora kinases: therapeutic potential. Drugs Fut. (2005) 30(1):29–37.
  • MORTLOCK A, KEEN NJ, JUNG FH et al.: Progress in the development of selective inhibitors of Aurora kinases. Curr. Top. In Med. Chem. (2005) 5:199-213. 1180Expert Opin. Ther Patents (2005) 15(9) Recent and complete review on Aurora inhibitors.
  • GLOVER DM, LEIBOWITZ MH, MCLEAN DA, PARRY H: Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 81(1):95–105.
  • ••Groundbreaking paper describing the firsttime Aurora kinase and functions.
  • HU HM, CHUANG CK, LEE MJ, TSENG TC, TANG TK: Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aiel. DNA Cell Biol. (2000) 19(10:679–688.
  • SASAI K, KATAYAMA H, STENOIEN DL et al.: Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton (2004) 59(4):249–263.
  • CARMENA M, EARNSHAW WC: The cellular geography of aurora kinases. Nat. Rev. Mol Cell Biol. (2003) 4(11):842–854.
  • MARUMOTO T, HONDAS, HARA T et al.: Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem. (2003) 278(50:51786–51795.
  • CASTRO A, ARLOT-BONNEMAINS Y, VIGNERON S, LABBE JC, PRIGENT C, LORCA T: APC/fizzy-related targets Aurora-A kinase for proteolysis. EMBO Rep. (2002) 3( 5):457–462.
  • HIROTA T, KUNITOKU N, SASAYAMAT et al.: Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell (2003) 114(5):585–598.
  • KUFER TA, SILLJE HH, KORNER R, GRUSS 0J, MERALDI P, NIGG EA: Human TPX2 is required for targeting Aurora-A kinase to the spindle./ Cell Biol. (2002) 158(4):617–623.
  • BISCHOFF JR, ANDERSON L, ZHU Y et al.: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. (1998) 17(11):3052–3065.
  • ••This paper describes the two mammalianAurora-A and -B kinases and their over-expression in human colorectal tumours.
  • NEBEN K, KORSHUNOV A, BENNER A et al.: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. (2004) 64(9):3103–3111.
  • EWART-TOLAND A, BRIASSOULI P, DE KONING JP et al.: Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet. (2003) 34(0403–412.
  • EGAN KM, NEWCOMB PA, AMBROSONE CB et al.: STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis (2004) 25(10:2149–2153.
  • MIAO X, SUN T, WANG Y, ZHANG X, TAN W, UN D: Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res. (2004) 64(8):2680–2683.
  • JENG YM, PENG SY, UN CY, HSU HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. (2004) 10(6):2065–2071.
  • CHEN SS, CHANG PC, CHENG YW, TANG FM, UN YS: Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J. (2002) 21(17):4491–4499.
  • LIU Q, KANEKO S, YANG L, FELDMAN RI et al.: Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol Chem. (2004) 279(50):52175–52182.
  • KATAYAMA H, SASAI K, KAWAI H et al.: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. (2004) 36(1):55–62.
  • CARPINELLI P, GIANELLINI L, SONCINI C et al.: Exploring the molecular mechanisms of a small molecule inhibitor of Aurora kinases. 96th Annual AACR Meeting, Anaheim: USA (2005). Astract 663.
  • CASTEDO M, PERFEEIINI JL, ROUMIER T, ANDREAU K, MEDEMA R, KROEMER G: Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 23(16):2825–2837.
  • VOGEL C, KIENITZ A, HOFMANN I, MULLER R, BASTIANS H: Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene (2004) 23(41):6845–6853.
  • EGGERT US, KIGER AA, RICHTER C et al.: Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS. Biol (2004) 2(12):e379–.
  • HATA T, F URUKAWA T, SUNAMURA M, EGAWA S, MOTOI F, OHMURA N, MARUMOTO T, SAYA H, HORII k RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. (2005) 65(7):2899–2905.
  • JONKERS J, BERNS A: Oncogene addiction: sometimes a temporary slavery. Cancer Cell (2004) 6(6):535–358.
  • KLEBL B: KinaTor & MasterKey: a chemoproteomics-driven medicinal chemistry approach to kinase inhibitor-based drug development. Protein kinase targets - IBC Conference, Innovations, Opportunities and Real Case Studies, Amsterdam, NE (2004).
  • DITCHFIELD C, JOHNSON VI., TIGHE A et al.: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell. Biol. (2003) 161(2):267–280.
  • •Cellular and molecular mechanism of action of an Aurora inhibitor (ZM447439) on cells and its effects on the spindle checkpoint.
  • MORTLOCK A, KEEN N, JUNG F et al.: Development of a new series of thiazolo-quinazoline inhibitors targeting Aurora kinase 95th Annual AACR Meeting. Orlando, USA (2004). Abstract 2480.
  • WILKINSON RW, KEEN N, WEDGE SR et al.: Development and characterization in vivo of an inhibitor with Aurora kinase A and B specificity. 95th Annual AACR Meeting. Orlando, USA (2004). Abstract 842.
  • Vertex inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase. Expert Opin. Ther. Patent (2004) 14(3):439–443.
  • GOLEC JMC: Perspectives on the discovery of VX-680, a selective inhibitor of the Aurora kinases. 229th ACS National Meeting. San Diego, USA. (2005). MEDI–307.
  • HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Medicine (2004) 10(3):262–327.
  • ••The first description of in vivo activity ofan Aurora inhibitor (VX-680) in animal tumour models.
  • DOGGRELL SA: Dawn of Aurora kinase inhibitors as anticancer drugs. Expert Opin. Investig Drugs (2004) 13(9):1199–1201.
  • FANCELLI D, BERTA D, BINDI S et al.: al Potent and Selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. (2005) 48(8):3080–3084.
  • HAUF S, COLE RW, LATERRA S et al: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. (2003) 161(2):281–294.

Websites

  • http://www.rigel.com/rigel/oncology Rigel pipeline.
  • http://www.sunesis.com/pipeline-programs.php Sunesis Programs.
  • http://www.astex-technology.com/ current_portfolio.html Astex Therapeutics.
  • http://www.merck.com/newsroom/ press_releases/research_and_development Merck research and development news.
  • http://www.nervianoms.com Nerviano Medical Sciences.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.